Key Takeaways
- • Benchmark Electronics (NYSE: BHE) raised full-year 2026 revenue growth guidance to 9–10% from prior mid-single-digit expectations, signaling accelerated momentum across key segments.
- • Q1 2026 revenue reached $677 million, up 7% year-over-year, with non-GAAP EPS of $0.58 at the upper end of guidance ($0.53–$0.59 range).
- • Medical segment revenue surged 24% year-over-year with expected continued momentum; AC&C revenue jumped 41% year-over-year, driven by AI infrastructure wins leveraging liquid cooling capabilities.
- • Semi-conductor capital equipment revenue declined modestly year-over-year but increased 12% sequentially; Industrial and A&D segments each declined 32% year-over-year as expected.
- • Cash position strengthened to $325 million with $121 million net cash at quarter end; available liquidity reached $486 million including $145 million outstanding term loan and $60 million revolver capacity.
Summary
Benchmark Electronics reported Q1 2026 results on April 29, 2026, demonstrating momentum across high-margin business segments while raising full-year guidance. The company generated $677 million in revenue, representing 7% year-over-year growth and positioning results at the higher end of prior guidance ranges. Non-GAAP EPS reached $0.58, exceeding the midpoint of the $0.53–$0.59 guidance range, though margin compression occurred sequentially due to volume changes and increased variable compensation costs.
The earnings beat and upgraded outlook reflect strength in AI-infrastructure and medical-device segments, which management highlighted as pivotal growth drivers. Medical revenue accelerated 24% year-over-year with sustained momentum expected in coming quarters, while the AC&C (Applications, Computing & Cloud) segment surged 41% year-over-year, primarily driven by initial ramp of AI-related customer wins that leverage the company's liquid cooling capabilities. Conversely, Semi-cap revenue declined slightly year-over-year but recovered 12% sequentially on a broad-based improvement basis, while Industrial and A&D segments each contracted 32% year-over-year in line with management expectations.
Operationally, non-GAAP gross margin improved 20 basis points year-over-year to reach 10.3%, though declined 30 basis points sequentially attributable to volume dynamics. Non-GAAP operating margin expanded 20 basis points year-over-year to 4.8% but contracted 70 basis points sequentially. Operating cash flow generated $47 million in Q1, with free cash flow of $29 million despite elevated inventory and capital investments. Capital expenditures totaled $18 million, positioning full-year capex at the upper end of the 2.0%–2.5% revenue range.
The balance sheet remained robust, with cash balances of $325 million (up $3 million sequentially) and a net positive cash position of $121 million at quarter end. Available liquidity reached $486 million, comprised of $145 million outstanding on term loan and $60 million on the revolver facility. The elevated guidance reflects management confidence in sustained demand for AI infrastructure solutions and medical technology applications, positioning Benchmark for accelerating growth through the remainder of 2026.
The earnings beat and upgraded outlook reflect strength in AI-infrastructure and medical-device segments, which management highlighted as pivotal growth drivers. Medical revenue accelerated 24% year-over-year with sustained momentum expected in coming quarters, while the AC&C (Applications, Computing & Cloud) segment surged 41% year-over-year, primarily driven by initial ramp of AI-related customer wins that leverage the company's liquid cooling capabilities. Conversely, Semi-cap revenue declined slightly year-over-year but recovered 12% sequentially on a broad-based improvement basis, while Industrial and A&D segments each contracted 32% year-over-year in line with management expectations.
Operationally, non-GAAP gross margin improved 20 basis points year-over-year to reach 10.3%, though declined 30 basis points sequentially attributable to volume dynamics. Non-GAAP operating margin expanded 20 basis points year-over-year to 4.8% but contracted 70 basis points sequentially. Operating cash flow generated $47 million in Q1, with free cash flow of $29 million despite elevated inventory and capital investments. Capital expenditures totaled $18 million, positioning full-year capex at the upper end of the 2.0%–2.5% revenue range.
The balance sheet remained robust, with cash balances of $325 million (up $3 million sequentially) and a net positive cash position of $121 million at quarter end. Available liquidity reached $486 million, comprised of $145 million outstanding on term loan and $60 million on the revolver facility. The elevated guidance reflects management confidence in sustained demand for AI infrastructure solutions and medical technology applications, positioning Benchmark for accelerating growth through the remainder of 2026.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.